Tanapun Thamgrang

Dr. Tanapun Thamgrang

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in Case Reports in Hematology
Verified
Journal Article
Open access
TUTaksin Ukkahad
Taksin Ukkahad
TTTanapun Thamgrang
Tanapun Thamgrang
Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions (MLN‐TK) represent rare hematological malignancies driven by pathological fusion genes involving tyrosine kinase genes. Among these, rearrangements of the PDGFRB gene, particularly the ETV6::PDGFRB rearrangement, are frequently observed as pathogenic mutations. Conversely, instances of the MPRIP::PDGFRB fusion gene are rarely documented. In this case report, we present a 32‐year‐old previously healthy Thai male who presented to the hospital with constitutional symptoms and marked splenomegaly. His complete blood count revealed mild anemia, marked leukocytosis with hypereosinophilia, and mild thrombocytopenia. A bone marrow study showed hypercellular marrow with granulocytic hyperplasia extensively involved with eosinophils, without morphological evidence of blasts. Conventional cytogenetics identified a t (5; 17) (q33; p13). Further targeted RNA analysis using next‐generation sequencing (NGS) detected a fusion gene involving MPRIP::PDGFRB . The patient was diagnosed with myeloid/lymphoid neoplasms with eosinophilia and MPRIP::PDGFRB rearrangement in the chronic‐phase disease and was initiated on oral imatinib at a daily dose of 100 mg. One month after initiating the treatment, the patient achieved a hematological response consistent with complete response (CR) criteria. Imatinib therapy has been well‐tolerated without reported adverse events, and a 1‐year molecular assessment confirmed the achievement of complete molecular response (CMR).

25 November 2025 in Hematology Reports
Verified
Journal Article
Open access
PDF file
KPKannadit Prayongratana
Kannadit Prayongratana
TTTanapun Thamgrang
Tanapun Thamgrang
CLChonlada Laoruangroj
Chonlada Laoruangroj
LNLalita Norasetthada
Lalita Norasetthada
TRThanawat Rattanathammethee
Thanawat Rattanathammethee
TITanin Intragumtornchai
Tanin Intragumtornchai
Objective: To describe the epidemiology, survival rate, and prognostic factors of mucosal-associated lymphoid tissue (MALT) lymphoma. Patients and Methods: This investigation utilized the Thai Lymphoma Study Group (TLSG) registry to gather data on patients diagnosed with MALT lymphoma. The analysis included demographic details, therapeutic interventions, and survival statistics. Results: The TLSG registry prospectively included 8404 patients with lymphoma. Among them, marginal-zone lymphoma (MZL) was the second most common subtype, with 670 histologically confirmed cases, accounting for 8.0% of the total cohort. An analysis of the MZL subtypes showed that MALT lymphoma was the most common, accounting for 77.8% of the diagnoses. This was followed by nodal MZL at 17.5% and splenic MZL at 7.7%. The distribution of primary disease sites indicated that the ocular adnexa (49.2%), stomach (12.9%), and sinonasal region (12.5%) were the three most common locations. Three variables were found to be statistically significant predictors of survival in the multivariate analysis: ECOG performance status > 2, age exceeding 65 years, and involvement of more than two extranodal organs. These identified prognostic factors were further assessed for their effect on overall survival (OS) and progression-free survival (PFS). A risk classification was established: the low-risk group comprised patients with zero identified risk factors, whereas the high-risk group included patients who had any of the specified risk factors. A comparison of five-year survival rates showed significantly more favorable outcomes for low-risk patients who had a PFS of 83.3% (vs. 66.1%, p = 0.028) and an OS of 97.8% (vs. 76.7%, p < 0.001) compared to the high-risk group. Conclusions: In this cohort, where MZL was the second most common lymphoma and MALT lymphoma was the predominant subtype, our analysis revealed that patients with no risk factors experienced statistically significant improvements in both PFS and OS.

1 August 2026 in Journal of Clinical Medicine Research
Verified
Journal Article
Open access
PDF file
TTTanapun Thamgrang
Tanapun Thamgrang
PTPakkapol Thiwannarak
Pakkapol Thiwannarak
PSPornpavee Siricharoenthai
Pornpavee Siricharoenthai
KPKannadit Prayongratana
Kannadit Prayongratana
CLChonlada Laoruangroj
Chonlada Laoruangroj
RLRattapan Lamool
Rattapan Lamool
Background: Data on anticoagulant-associated bleeding among patients with venous thromboembolism (VTE) in Southeast Asia are limited. We aimed to determine the incidence and predictors of anticoagulant-associated bleeding and evaluate its association with mortality. Methods: We conducted a retrospective cohort study of patients with VTE treated with anticoagulants between January 2014 and June 2024. Clinically relevant bleeding (CRB) was defined according to the International Society on Thrombosis and Haemostasis criteria. Cumulative incidence was estimated using the Aalen–Johansen method with death as a competing event, and predictors were identified using Fine–Gray sub-distribution hazard models. The association between bleeding and all-cause mortality was evaluated using time-dependent Cox proportional hazards models. Results: Among 395 patients (mean age, 60.7 ± 16.2 years; 65.3% female), 43.5% had cancer-associated thrombosis. Low-molecular-weight heparin was the most commonly prescribed initial anticoagulant (39.0%), followed by warfarin (32.7%) and direct oral anticoagulants (25.1%), of which apixaban was the most frequently used (12.7%). During a median follow-up of 0.88 years, 60 patients (15.2%) developed CRB. The 1-year cumulative incidence of CRB was 14.89% (95% confidence interval (CI), 11.09–19.23). Independent predictors of CRB included concomitant antiplatelet therapy (adjusted sub-distribution hazard ratio (aSHR), 3.48; 95% CI, 1.76–6.90), Eastern Cooperative Oncology Group performance status ≥ 2 (aSHR, 3.05; 95% CI, 1.34–6.94), body mass index (BMI) < 20 kg/m2 (aSHR, 2.50; 95% CI, 1.36–4.61), and age ≥ 65 years (aSHR, 1.97; 95% CI, 1.12–3.45). Both clinically relevant non-major bleeding (adjusted hazard ratio (aHR), 3.72; 95% CI, 1.55–8.92) and major bleeding (aHR, 5.62; 95% CI, 2.91–10.85) were independently associated with increased all-cause mortality. Conclusions: Anticoagulant-associated bleeding is common among Thai patients with VTE and is associated with an increased risk of all-cause mortality. Patients with advanced age, poor performance status, low BMI, or concomitant antiplatelet therapy may benefit from closer monitoring during anticoagulant treatment.

6 February 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
TTTanapun Thamgrang
Tanapun Thamgrang
TSTotai Seeboonruang
Totai Seeboonruang
DADollapak Apipongrat
Dollapak Apipongrat
RLRattapan Lamool
Rattapan Lamool
BackgroundApixaban prolongs the dilute Russell’s viper venom time (dRVVT), which may serve as a rapid surrogate for identifying clinically relevant drug concentrations in urgent settings.ObjectivesTo evaluate the correlation between dRVVT and apixaban concentration, and to establish cut-off values for clinically relevant thresholds (≥30 and ≥50 ng/mL).MethodsThis cross-sectional study included 104 patients receiving apixaban. Normalized dRVVT screening and confirmation ratios were compared with chromogenic anti–factor Xa–based apixaban concentrations. Correlations were evaluated using Spearman’s rank correlation coefficient (ρ). The ROC curve analysis with the Youden index was performed to identify optimal diagnostic cut-offs.ResultsThe median apixaban concentration was 116.3 ng/mL (IQR, 78.9–177.2), with ≥30 ng/mL observed in 96.2%. Moderate correlations were observed between dRVVT ratios and apixaban concentrations for both screening and confirmatory assays (ρ = 0.675 [95% CI, 0.554–0.786] and 0.713 [95% CI, 0.604–0.797], respectively). Both dRVVT ratios showed comparable discriminative ability for detecting concentrations ≥50 ng/mL (AUC, 0.885 vs. 0.892; P = 0.690) and ≥30 ng/mL (AUC, 0.956 vs. 0.975; P = 0.446). Optimal cut-off values (screening/confirmation) for ≥50 ng/mL were 1.33/1.42, with sensitivities of 82.8%/84.9% and specificities of 90.9%. For ≥30 ng/mL, cut-offs of 1.12/1.16 provided sensitivities of 92.0%/96.0% and specificities of 100%.ConclusionsdRVVT assays correlate moderately with apixaban concentrations. dRVVT may support semi-quantitative assessment and rule-in of apixaban exposure; however, it cannot reliably exclude low drug levels. The low prevalence of subthreshold concentrations may limit specificity precision, warranting caution in borderline or high-risk clinical scenarios.

9 February 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
PSPornpavee Siricharoenthai
Pornpavee Siricharoenthai
CTChanunya Thanoochan
Chanunya Thanoochan
PSPanachai Silpsamrit
Panachai Silpsamrit
KPKannadit Prayongratana
Kannadit Prayongratana
CLChonlada Laoruangroj
Chonlada Laoruangroj
TTTanapun Thamgrang
Tanapun Thamgrang
Background: The 2024 International Myeloma Society–International Myeloma Working Group consensus classifies elevated β2-microglobulin (β2M) with normal serum creatinine (SCr) as high-risk multiple myeloma (MM). However, creatinine-based renal definitions may be inaccurate in Asian populations with lower muscle mass.Aims: To evaluate the prognostic impact of isolated elevated β2M on overall survival (OS) using SCr– and creatinine clearance (CrCl)-based definitions of renal function.Methods: This retrospective study included newly diagnosed MM patients (2006–2023). Patients were classified as Group A (β2M ≤5.5 mg/L), Group B (β2M >5.5 mg/L, SCr 5.5 mg/L, SCr ≥1.2 mg/dL). In secondary analyses, renal function was redefined using CrCl (≥60 mL/min).Results: Among 250 patients (mean age 61.0±12.1 years; 62.0% male), 34.4% underwent autologous stem cell transplantation. Groups A, B, and C included 110 (44.0%), 29 (11.6%), and 111 (44.4%) patients, respectively. At a median follow-up of 4.6 years, 4-year OS for Groups A, B, and C was 80.0%, 71.6%, and 59.5% (P=0.009). Group B did not demonstrate significantly inferior OS compared with Group A (adjusted hazard ratio [aHR], 1.53; 95% CI, 0.71–3.28), whereas Group C had significantly worse OS (aHR, 1.86; 95% CI, 1.16–3.00). When renal function was defined by CrCl, reclassified Group B (n=19) showed significantly inferior OS (aHR, 2.42; 95% CI, 1.07–5.45).Conclusions: Elevated β2M with normal SCr failed to show independent prognostic significance in this cohort. However, CrCl-based definitions improved prognostic stratification, suggesting that standard creatinine thresholds may underestimate risk in Thai patients.

10 April 2026 in Thrombosis Research
Verified
Journal Article
Closed access
TSTotai Seeboonruang
Totai Seeboonruang
DADollapak Apipongrat
Dollapak Apipongrat
RLRattapan Lamool
Rattapan Lamool
TTTanapun Thamgrang
Tanapun Thamgrang